DNA Synthesis Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Service Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

DNA Synthesis Market size was more than USD 4.5 billion in 2026 and is set to grow at a 16.44% CAGR between 2027 and 2036, surpassing USD 20.62 billion by 2036. The industry revenue for 2027 is calculated at USD 5.12 billion.

• Base Year Value (2026): USD 4.5 billion
• CAGR (2027-2036): 16.44%
• Forecast Year Value (2036): USD 20.62 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

DNA Synthesis Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 42.22% of the market in 2026, supported by advanced biotechnology research, strong pharmaceutical activity, and sustained demand for high-throughput DNA synthesis services.
  • Asia Pacific is forecast to grow at a 17.02% CAGR as biotechnology research expands, laboratory capacity increases, and synthetic biology adoption supports faster research and product development.

• Segment Momentum:

  • Research and Development accounted for 61.59% of the market in 2026, driven by recurring demand for synthetic DNA in experimental design, target validation, assay optimization, and platform testing across research settings.
  • Contract Research Organizations are growing fastest as companies increasingly outsource DNA synthesis to access flexible research capacity, scalable project execution, and specialized expertise without expanding in-house infrastructure.

• Market Expansion Drivers:

  • Expanding synthetic biology and genetic engineering applications driving demand for custom DNA constructs.
  • Rising biopharmaceutical R&D and precision medicine accelerating oligonucleotide synthesis adoption.
  • Technological advancements enabling high-throughput and long-read DNA synthesis platforms improving scalability.

• Leading Market Participants:

  Leading companies in the DNA synthesis market include Thermo Fisher Scientific Inc. (United States), Twist Bioscience Corporation (United States), BIONEER Corporation (South Korea), Eton Bioscience, Inc. (United States), LGC Biosearch Technologies (United Kingdom), IBA Lifesciences GmbH (Germany), Eurofins Scientific SE (Luxembourg), Integrated DNA Technologies, Inc. (United States), Quintara Biosciences, Inc. (United States), GenScript Biotech Corporation (China).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 4.5 billion
  • 2027 Estimated Market Size: USD 5.12 billion.
  • Projected Market Size: USD 20.62 billion by 2036
  • Growth Forecasts: 16.44% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Biopharmaceutical and Diagnostics Companies (End-use) | Research and Development (Application) | Oligonucleotide Synthesis (Service Type)
  • Emerging Opportunity Segment: Contract Research Organizations (End-use) | Gene Synthesis (Application) | Gene Synthesis (Service Type)

Market Growth Drivers and Industry Trends

Expanding synthetic biology and genetic engineering applications driving demand for custom DNA constructs

The DNA synthesis market growth is being propelled by the expanding use of synthetic biology and genetic engineering across research and development activities. Researchers increasingly require custom DNA sequences, genes, plasmids, and other constructs to design biological systems, modify cellular functions, and develop engineered organisms for specialized applications. The ability to obtain tailored DNA constructs supports experimentation across areas such as metabolic engineering, functional genomics, and biological pathway development, while greater flexibility in sequence design enables researchers to address application-specific requirements and accelerate laboratory workflows.

Rising biopharmaceutical R&D and precision medicine accelerating oligonucleotide synthesis adoption

Rising biopharmaceutical research activity is creating stronger demand for synthesis capabilities, particularly as precision medicine approaches require increasingly targeted genetic and molecular interventions. Within the DNA synthesis market, oligonucleotide synthesis supports the development and validation of nucleic acid-based research tools, diagnostic applications, therapeutic candidates, and personalized treatment strategies. As drug discovery increasingly incorporates sequence-specific approaches and researchers require customized genetic materials for disease investigation, synthesis providers are being positioned to support more specialized development programs and complex research workflows.

Technological advancements enabling high-throughput and long-read DNA synthesis platforms improving scalability

Technological advancements in synthesis methods are improving the ability of the DNA synthesis market to accommodate larger volumes and more complex sequence requirements. High-throughput platforms allow multiple DNA constructs to be produced efficiently, supporting large-scale screening, library generation, and parallel experimentation, while long-read synthesis capabilities expand the feasibility of producing longer and more intricate genetic sequences. Improvements in automation, sequence accuracy, and workflow integration can also reduce operational complexity and make customized DNA production more practical for laboratories handling increasingly sophisticated biological engineering projects.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Expanding synthetic biology and genetic engineering applications driving demand for custom DNA constructs	2.40%	High	North America, Europe	High	Near Term
Rising biopharmaceutical R&D and precision medicine accelerating oligonucleotide synthesis adoption	2.10%	High	North America, Asia Pacific	High	Near Term
Technological advancements enabling high-throughput and long-read DNA synthesis platforms improving scalability	1.80%	High	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 42.22% share of the DNA synthesis market in 2026, supported by a mature biotechnology ecosystem, strong life sciences research capabilities, and extensive use of synthetic DNA across genomics, drug discovery, diagnostics, and molecular biology. Advanced laboratory infrastructure and sustained investment in genetic research are encouraging broader adoption of increasingly sophisticated synthesis technologies. The region's established research institutions and expanding applications in biotechnology and precision medicine further support demand for reliable, high-quality DNA synthesis solutions.

Asia Pacific is the fastest-growing region, driven by expanding biotechnology research, growing pharmaceutical development capabilities, and increasing investment in genomics infrastructure. Greater adoption of molecular biology techniques is creating new applications for synthetic DNA across research, diagnostics, and therapeutic development. Improvements in laboratory capabilities and increasing focus on domestic life sciences innovation are also supporting wider access to DNA synthesis technologies, creating favorable conditions for rapid regional market expansion.

Key Country Insights

United States

Biotech scale-up ecosystems

In the U.S., DNA synthesis demand is driven by highly developed biotech ecosystems where rapid prototyping and large-scale research programs are common. The U.S. emphasizes integration of synthetic biology into pharmaceuticals and research pipelines, supporting fast iteration in genetic design and therapeutic development workflows.

Japan

Genomics research integration

In Japan, DNA synthesis is closely tied to advanced genomics research and academic-industry collaboration frameworks. Japan emphasizes high-accuracy synthesis for life sciences innovation, particularly in areas such as disease research and molecular biology, where precision and reliability are central requirements.

South Korea

Bio-manufacturing acceleration

In South Korea, DNA synthesis adoption is expanding alongside rapidly scaling bio-manufacturing and synthetic biology initiatives. South Korea focuses on integrating synthesis capabilities into industrial biotech platforms, supporting faster development cycles in pharmaceuticals and engineered biological systems.

Germany

Industrial biotech precision

In Germany, DNA synthesis is shaped by strong industrial biotechnology capabilities with emphasis on precision, quality control, and reproducibility. Germany focuses on structured adoption in pharmaceutical and chemical research environments, where synthetic DNA supports advanced R&D and controlled experimental applications.

France

Pharmaceutical R&D alignment

In France, DNA synthesis is primarily driven by pharmaceutical research institutions and biotech clusters focused on drug discovery. France emphasizes structured integration of synthetic DNA tools into R&D pipelines, supporting molecular innovation within regulated therapeutic development environments.

Italy

Academic biotech specialization

In Italy, DNA synthesis activity is concentrated within academic and specialized biotech research settings. Italy focuses on supporting targeted scientific studies in molecular biology and genetics, where synthesis capabilities enable experimental research and early-stage innovation in life sciences.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Biopharmaceutical and Diagnostics Companies (Largest Segment) vs Contract Research Organizations (Fastest-Growing Segment)

In the DNA synthesis market, biopharmaceutical and diagnostics companies represented the largest end-use segment, accounting for 52.61% in 2026. Demand is supported by extensive use of synthetic DNA in therapeutic research, molecular diagnostics, assay development, and the design of biological products. Increasing reliance on customized genetic sequences and advanced molecular workflows is encouraging these organizations to incorporate DNA synthesis into research and development activities, supporting sustained segment leadership.

Contract research organizations are gaining importance as biopharmaceutical and research activities increasingly rely on outsourced scientific capabilities. These organizations provide specialized research support that can include synthetic DNA requirements for experimental development, assay work, and preclinical studies. The growing use of external research expertise, combined with demand for flexible and scalable molecular biology services, is strengthening DNA synthesis adoption within this end-use segment.

Application Segment Analysis: Research and Development (Largest Segment) vs Gene Synthesis (Fastest-Growing Segment)

The research and development segment led the DNA synthesis market with a 61.59% share in 2026, reflecting the extensive role of synthetic DNA in exploratory research, molecular biology, therapeutic discovery, and biotechnology development. Researchers use custom DNA sequences to investigate gene function, develop experimental constructs, validate biological hypotheses, and support the advancement of novel biological applications. Continued innovation across life sciences is sustaining strong demand for DNA synthesis within R&D workflows.

Gene synthesis is expanding rapidly as researchers increasingly require precisely designed genetic sequences for applications ranging from protein engineering to functional genomics. The ability to obtain customized sequences supports faster experimentation and enables the development of complex biological constructs that may be difficult to obtain through conventional methods. Rising interest in engineered biology, genetic modification, and customized research tools is creating stronger demand for gene synthesis applications.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Biopharmaceutical and Diagnostics Companies, Academic and Research Institutes, Contract Research Organizations	Biopharmaceutical and Diagnostics Companies	Contract Research Organizations
Application	Research and Development, Gene Synthesis, Diagnostics, Therapeutics	Research and Development	Gene Synthesis
Service Type	Oligonucleotide Synthesis, Gene Synthesis	Oligonucleotide Synthesis	Gene Synthesis

Competitive Landscape and Market Positioning

Major players in the DNA synthesis market:

1. Thermo Fisher Scientific Inc. (United States)

2. Twist Bioscience Corporation (United States)

3. BIONEER Corporation (South Korea)

4. Eton Bioscience Inc. (United States)

5. LGC Biosearch Technologies (United Kingdom)

6. IBA Lifesciences GmbH (Germany)

7. Eurofins Scientific SE (Luxembourg)

8. Integrated DNA Technologies Inc. (United States)

9. Quintara Biosciences Inc. (United States)

10. GenScript Biotech Corporation (China)

The DNA synthesis market is evolving through rapid advancements in precision biotechnology and automated synthesis processes. New synthesis platforms are being introduced to improve speed and accuracy in genetic construction. Research efforts are enhancing scalability and sequence fidelity. Expanding biotech ecosystems are also supporting broader applications in therapeutics and research.

Industry Development/News

Company Name	Date	Key Development
Atlas Data Storage	Mar-25	Atlas Data Storage acquired DNA data storage assets from Twist Bioscience and completed a seed funding round. This transaction consolidates critical intellectual property and capital, significantly strengthening the company’s technology foundation to advance the commercialization of synthetic DNA-based digital data storage solutions.
Integrated DNA Technologies	Feb-25	Integrated DNA Technologies expanded its operational footprint by opening a new synthetic biology manufacturing facility in Coralville, Iowa. This dedicated plant increases production capacity for synthetic DNA products, supporting the company’s ability to meet growing market demand and scale its output for research and industrial applications.
Elegen	Feb-25	Elegen secured $35 million in funding from investors including Triatomic Capital and GSK. This capital injection is targeted at accelerating the production of GMP-compliant DNA products and scaling the company’s long-DNA synthesis capabilities to better serve clinical and biopharmaceutical development requirements.
Twist Bioscience	May-25	Twist Bioscience restructured its long-standing collaboration with Ginkgo Bioworks into a three-year agreement. The revised terms include the acquisition of specific long-DNA technology licenses and reagents by Twist, enhancing its technical portfolio and strengthening its competitive position within the synthetic biology and DNA synthesis landscape.
Ansa Biotechnologies	Mar-25	Ansa Biotechnologies launched a 50 kb sequence-perfect clonal DNA product, representing a significant advancement in synthetic biology. By providing the longest commercially verified synthetic DNA construct available, the company enables researchers to rapidly access ultra-long, high-fidelity sequences, addressing a critical bottleneck in biotechnology and gene therapy development.
Integrated DNA Technologies	Mar-25	Integrated DNA Technologies partnered with Elegen to offer early access to ENFINIA Plasmid DNA services. This collaboration enables the rapid delivery of complex clonal genes up to 15 kb, significantly enhancing the company’s synthetic biology portfolio and providing customers with accelerated workflows for gene therapy and metabolic engineering.
DNA Script	Mar-25	DNA Script expanded its global commercial reach by signing multiple distribution agreements with Gencell, Bio-Medical Science, and Biostream. These partnerships facilitate the wider international adoption of the company's proprietary SYNTAX platform, streamlining access to benchtop DNA synthesis technology for research and clinical laboratories worldwide.
Twist Bioscience	Feb-25	Twist Bioscience entered a strategic collaboration with Absci to integrate its DNA synthesis platform with Absci’s artificial intelligence capabilities. This partnership focuses on high-throughput antibody discovery, aiming to accelerate the design and development cycle for novel therapeutic candidates through the synergistic application of synthetic biology and machine learning.
Biomemory	Mar-25	Biomemory announced significant progress in the deployment of its DNA data storage technology within data center environments. This milestone marks a transition toward commercial scalability for synthetic DNA-based systems, specifically targeting the burgeoning demand for high-density, long-term digital data preservation solutions.
GenScript Biotech	Jun-24	GenScript Biotech introduced its FLASH Gene service, an ultra-fast sequence-to-plasmid solution capable of delivering gene constructs in four business days. Operating from its expanded New Jersey facility, this service enhances global research productivity by offering high-fidelity gene synthesis and cloning, supporting accelerated development in vaccine and cell therapy pipelines.